Hoth Therapeutics (HOTH) said Tuesday interim results from a phase 2a trial of HT-001 showed that all patients met the primary efficacy endpoint.
The trial demonstrated improvements in skin toxicities caused by epidermal growth factor receptor inhibitors, with all patients maintaining full cancer treatment doses, the company said.
Hoth reported no treatment-related adverse effects, noting HT-001's safety and tolerability.
The company's shares were up over 94% in recent early Tuesday trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。